Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Coya Therapeutics Appoints Arun Swaminathan Ph.D. As Chief Executive Officer, Succeeding Dr. Howard Berman

PUBLIC · COYAAug 19, 2024•almost 2 years ago

Position

Chief Executive Officer

Company

Coya Therapeutics

Arun Swaminathan

HoustonBiotechnology

Description

Coya Therapeutics, Inc announced the promotion of Arun Swaminathan PhD to the role of Chief Executive Officer, effective November 1, 2024. He will succeed Dr Howard Berman, who will continue to serve in the capacity of Executive Chair.

Company Information

Company

Coya Therapeutics

Location

Houston, Texas, United States

About

Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Coya Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months